1st Quarter of Fiscal 2023 Financial Results

July 31, 2023 Shionogi & Co., Ltd.



Agenda

- 1. Overview of Q1 FY2023 Financial Results (P.3-9)
- 2. Main Activities and Achievements in Q1 FY2023 (P.10-17)
- 3. Shareholder Return (P.18-19)




1. Overview of Q1 FY2023 Financial Results



Financial Highlights

- Revenue and all profit categories increased YoY
- Despite continued aggressive investment, revenue and all profit reached record highs in 1Q



* Earnings Before Interest, Taxes, Depreciation, and Amortization: Operating profit added depreciation and adjusted for one-time factors (impairment losses, gain on sale of property, plant and equipment, etc.)

🚺 SHIONOGI

Financial Results

(Unit : B yen)

	FY2023				FY2022	Y on	γ
	Forecas Full year	sts 1H	AprJun. Results	Achievement (%)	AprJun. Results	Change(%)	Change
Revenue	450.0	217.0	109.3	50.4	71.8	52.2	37.5
Operating profit	150.0	80.5	46.6	57.9	12.4	275.0	34.2
Profit before tax	192.5	98.0	55.7	56.8	40.3	38.2	15.4
Profit attributable to owners of parent	155.0	78.0	42.6	54.6	34.7	22.6	7.8

		FY2023 Forecasts	FY2023 AprJun. Results
	USD(\$) – JPY(¥)	130	137.50
Exchange Rate (Average)	GBP(£) – JPY(¥)	160	172.13
	EUR(€) – JPY(¥)	140	149.59



Statement of Profit or Loss

						(011	п. ь yen)	
		F١	/2023		FY2022	Y on	Υ	
	Fore Full year	cast 1H	AprJun. Results	Achievement (%)	AprJun Results	Change(%)	Change	
Revenue	450.0	217.0			71.8	52.2	37.5	
Cost of Sales	15.3	14.5	12.0		18.0			•
	69.0	31.5	13.1	41.6	12.9	1.3	0.2	
Gross profit	381.0	185.5	96.2	51.9	58.9	63.3	37.3	
Selling, general &	50.9	47.7	44.9		63.9			
administrative expenses, R&D expenses total	229.0	103.5	49.0	47.4	45.9	6.8	3.1	•
Selling, general &	28.9	24.9	22.0		32.6			
administrative expenses	130.0	54.0	24.0	44.5	23.4	2.7	0.6	
	22.0	22.8	22.9		31.4			
R&D expenses	99.0	49.5	25.0	50.5	22.5	10.9	2.5	
Other income & expenses	(2.0)	(1.5)	(0.6)	37.8	(0.5)	5.8	(0.0)	•
On constinue and fit	33.3	37.1	42.6		17.3			
Operating profit	150.0	80.5	46.6	57.9	12.4	275.0	34.2	
Finance income & costs	42.5	17.5	9.1	52.1	27.9	(67.3)	(18.8)	
	42.8	45.2	51.0		56.1			
Profit before tax	192.5	98.0	55.7	56.8	40.3	38.2	15.4	=
Profit attributable to owners of parent	155.0	78.0	42.6	54.6	34.7	22.6	7.8	

(Unit : B yen)

Main Variation Factors (Y on Y)

Revenue

Increase : Domestic sales, Overseas subsidiaries /export, Royalty income

R&D expenses

 Increase : Investment in R&D activities including COVID-19 related projects

Finance income & costs

- Decrease in income: Received dividend from ViiV
 - FY2022 dividend increased temporarily for the following reasons
 - Delayed receipt of dividends from ViiV which scheduled to be received in 4Q of FY2021
 - Increased dividends due to ViiV receipt of lump sum payment from settlement with Gilead
- ⇒ Dividends are progressing as planned, excluding temporary factors



* Sales revenue includes Lump-sum income for transfer of ADHD drug

Revenue by Segment

						(Un	it : B yen)
		FY	2023	023		Y on	Υ
	Forec Full year	ast 1H	AprJun Results	Achievement (%)	AprJun Results	Change(%)	Change
Prescription drugs	134.1	87.4	45.9	52.5	19.0	141.6	26.9
Overseas subsidiaries/export	96.6	28.0	12.0	42.8	8.8	36.2	3.2
Shionogi Inc. (US)	13.6	6.7	4.0	60.3	3.0	34.5	1.0
Fetroja	-	-	3.2	-	1.8	82.1	1.4
Shionogi B.V. (EU)	11.5	5.4	3.0	54.9	1.9	61.3	1.1
Fetcroja	-	-	2.1	-	1.4	57.4	0.8
Ping An Shionogi/C&O	58.0	13.2	3.1	23.4	2.5	22.2	0.6
Others	13.4	2.7	1.9	69.9	1.4	31.7	0.5
Contract manufacturing	13.8	7.3	4.0	54.7	3.4	19.1	0.6
OTC and quasi-drug	15.0	6.8	2.3	33.3	1.9	16.6	0.3
Royalty income	189.5	86.9	44.8	51.6	38.4	16.7	6.4
HIV franchise	185.0	86.0	44.3	51.4	37.3	18.7	7.0
Others	4.5	0.9	0.6	65.5	1.1	(47.6)	(0.5)
Others	1.0	0.5	0.3	58.6	0.3	(7.3)	(0.0)
Total	450.0	217.0	109.3	50.4	71.8	52.2	37.5

(Unit + Pyon)

٠

Main Variation Factors (Y on Y)

Prescription drugs

- Increase : Sales of Xocova : Receipt of Lump-sum income for transfer of ADHD drug
- Decrease: Sales of ADHD drug ٠

Overseas subsidiaries/export

- Increase: Sales of cefiderocol (Fetroja, Fetcroja) ٠
- Decrease: Change in Osphena sales scheme ٠

Royalty income

Increase: Strong sales of ViiV's HIV franchise •



Prescription Drugs in Japan

(Unit : B yen)

	FY2023				FY2022	Y on Y	
	Forecas Full year	it 1H	AprJun. Results	Achievement (%)	AprJun. Results	Change(%)	Change
Infectious disease drugs	65.7	40.0	9.3	23.1	2.1	348.9	7.2
COVID-19 related products + Influenza franchise	57.3	35.8	7.1	19.8	0.1	-	7.0
Cymbalta	4.2	2.1	1.1	52.6	1.7	(32.4)	(0.5)
OxyContin franchise	4.1	2.1	1.1	52.7	1.2	(6.8)	(0.1)
Symproic	4.9	2.3	1.0	45.2	0.8	29.7	0.2
Actair	1.0	0.4	0.1	35.0	0.1	13.9	0.0
Mulpleta	0.1	0.1	0.0	44.2	0.0	5.8	0.0
Pirespa	1.9	1.1	0.5	47.9	0.7	(25.7)	(0.2)
Others	52.1	39.3	32.7	83.2	12.5	162.5	20.3
ADHD drug (Intuniv and Vyvanse)	25.0	25.0	25.0	100.0	4.9	405.3	20.1
Prescription drugs	134.1	87.4	45.9	52.5	19.0	141.6	26.9

COVID-19 related products	Influenza franchise	Infectious disease drugs
XocovaCOVID-19 vaccines	 Xofluza Rapiacta BrightpocFlu·Neo 	 FINIBAX Flumarin Baktar Flomox Flagyl



First Quarter Results and Progress

All businesses are strong, with top-line growing significantly year-on-year

•	Domestic	FY2022 1Q Revenue	71.8 B yen	
	 Increased sales of Xocova outweighed decreased sales of ADHD drugs, resulting in overall growth 	Prescription dru	gs	+26.9
•	Overseas subsidiaries	Royalty income		+6.4
	 Strong growth of Cefiderocol (Fetroja, Fetcroja) 	Overseas subsid	aries/export	+3.2
•	Royalty Strong growth of Dovato, Cabenuva, Apretude 	Contract manufa	acturing	+0.6
•	Others	OTC and quasi-d	Irug	+0.3
	 Growth of Contract manufacturing and OTC and quasi-drug 	FY2023 1Q Revenue	109.3 B yen	+37.5
				B yen

At present, the forecast for the first half is expected to be achieved without revision

- Base business is expected to remain strong
- Steady penetration of Xocova and changes in current infection status



2. Main Activities and Achievements in Q1 FY2023



Xocova (Ensitrelvir): Current Domestic Situation and Development Plan Progress

Steady progress in each initiative toward global expansion

Current domestic situation

- Accumulation of safety and efficacy information from actual use
 - Early post-marketing surveillance:
 - > As a result of more than 70,000 prescriptions and safety evaluation results, it was evaluated that no additional safety measures were necessary in the deliberations of the Safety Measures Committee.

 \Rightarrow We will continue to provide regular feedback on safety information collected to healthcare professionals

- Post-Marketing Surveillance:
 - Currently collecting safety and efficacy information on 3,000 patients
 ⇒Prepared the first interim report*¹(June 2023)
 - Patient background: Over 80% do not have risk factors
 - Safety and efficacy: Results similar to clinical trials were obtained
- Under review by MHLW and PMDA for regular approval

Development plan progress

- First patients enrolled in further trials
 - Prevention: Global Phase 3 trial (SCORPIO-PEP trial)
 - Pediatric indication: Phase 3 Pediatric trial (Japan)
- Asia
 - China: Inquiries from authorities are being addressed
 - Korea: Under MFDS*² review for approval
 - Taiwan: Under TFDA*³ discussion for approval
- US/UK,EU
 - Global Phase 3 trials supported by NIH*⁴ progressing smoothly
 - > SCORPIO-HR trial、STRIVE trial



Progress of Vaccine Business

Various efforts toward building a sustainable business model are progressing

COVID-19 Vaccine : S-268019

- Scheduled for deliberation at the Second Pharmaceutical Subcommittee on July 31, 2023
 - Accelerate preparations for domestic supply
- LCM Initiatives to Maximize Value
 - Adult booster immunization (fourth vaccination), clinical trials in adolescents and school children are underway

Vaccine for COVID-19 Mutant strain

- Development of a monovalent vaccine for the Omicron XBB mutant is underway
 - Scheduled to enter clinical practice promptly after S-268019 is approved in Japan

Progress in universal vaccine development

- Good ability to induce neutralizing antibody confirmed in antigen design study of universal sarbecovirus vaccine
 - Anticipated as a preparation for new pandemics originating from mutated strains of the new coronavirus (SARS-CoV-2) that evade immunity and sarbecoviruses that may occur in the future'
 - Developed with KOTAI Biotechnologies, Inc. and the National Institute of Infectious Diseases under the support of SCARDA** of AMED**
- Aiming for clinical entry in 2024



Progress in Building Foundations for Global Expansion

Acquisition of pipeline and R&D capabilities by making Qpex Biopharma a wholly owned subsidiary

Purpose of making a subsidiary

- **1.** Acquisition of Xeruborbactam (β-lactamase inhibitor)
 - ⇒ Preparing for strains with low susceptibility to β -lactam antibiotics*
 - Broad inhibition spectrum that can inhibit a wide range of β-lactamases
- 2. Further strengthening of drug discovery and development of antibacterial drugs

⇒ Acquisition of human resources with unique chemistry and deep US antibacterial development knowledge


3. Strengthening external networks and cooperation

This project has been funded in whole or in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under OTA number HHSO100201600026C.

Need for Xeruborbactam

- One mechanism of bacterial drug resistance is the degradation of β -lactam antibiotics by bacterial β -lactamase.
- Xeruborbactam inhibits degradation of antimicrobials by βlactamase

Combined use of β -lactam antibacterial drug and Xeruborbactam makes it possible to demonstrate broad antibacterial activity against drug-resistant bacteria



* Cephalosporin, Carbapenem, Cephems, Penicillin, Monobactam

Progress of Major Development Products

as of July 30, 2023

Disease area	Pipeline	Indication	Current stage	FY2023	FY2024	Note
	Olorofim	Invasive aspergillosis	Phase 3	Completion	of Phase 3 case registration (4Q)	
Infection	S-337395	RSV infections	Phase 1	Phase 1 topline results		FPI* ¹ (April 2023)
	S-892216	COVID-19	Phase 1	Phase 1 topline results		FPI*1 (May 2023)
	Zuranolone	Depression	Phase 3	Phase 3 topline results (3Q) Sub	mission (4Q)	Add on trial LPI* ² (July 2023)
	Resiniferatoxin	Pain associated with knee osteoarthritis	Phase 3		Submission (4Q)	Breakthrough therapy designation* ³
	SDT-001	ADHD	Phase 3	Submission		
QOL Diseases	Zatolmilast	Fragile X Syndrome	Phase 2/3	Phase 2/3 toplir	ne results (2Q) Submission (3Q)	
with High Social Impact		Acute ischemic stroke	Phase 2b			
Social Impact	Redasemtide	Dystrophic epidermolysis bullosa	Phase 2		Submission (3Q)	Orphan drug designation*4
	S-309309	Obesity	Phase 2	Phase 2 topline result	ts (4Q) Phase 3 start	FPI*1 (July 2023)
	S-531011	Solid tumor	Phase 1b/2	Phase 2 start (4Q)		
	S-151128	Chronic pain	Phase 1	Phase 1 topline results		FPI* ¹ (April 2023)

topline results: It is the timing of acquisition, and the timing of disclosure will be considered separately



Development Progress of Medium- to Long-term Growth Drivers

S-309309: Phase 2 trial overview^{*1} and future plans


MGAT2*² inhibitor, novel mechanism of action

Country	U.S.		
Subject	Adults with a BMI of 30 or higher		
Design Multicenter, randomized, double-blind, dose-ranging, placebo-controlled			
Dosage Number of cases	 Oral once daily for 24 weeks S-309309: 3 doses, placebo,80 in each group (320 in total) 		
Primary endpoint	Percent change in body weight from baseline (week 24)		
Secondary endpoint	 Percentage of subjects achieving ≥5%/10%/15%/20% weight loss Waist circumference, waist/hip ratio, BMI, abdominal fat 		

Resiniferatoxin: favorable clinical trial results

TRPV1*⁴ agonist, non-opioid novel mechanism of action

Results from Phase 1 and 2




Plan to start global Phase 3 study immediately after obtaining POC^{*3} and determining optimal dose in this trial Grünenthal received breakthrough therapy designation from FDA based on significant pain relief and favorable safety profile



Progress of HIV Business by ViiV

Strong growth of oral two-drug regimens and LA formulations



- Sales ratio of innovative portfolio increased to 51%
- LA formulations
 - Cabenuva
 - > Compelling prescription growth driven by SOLAR study results*³
 - \Rightarrow >70% of sales from competitor regimens
 - Apretude
 - > Strong sales build in US
 - > Received positive CHMP opinion in Europe*4
- R&D pipeline includes multiple combination candidates for the creation of next-generation LA formulations
- Granted pediatric exclusivity by US FDA extending LOE by six months to April 2028



Human Capital Management Efforts to Achieve the 2030 Vision

Accelerate review of human resources portfolio to realize "global growth" and "establishment and growth of new businesses"

Initiatives introduced in the last few years

New personnel system

Re-grade

Measures to improve work comfort (working from home, 3 days off per week, permission to work as a side job, etc.)

Reskilling, retraining

(DX training, self-investment support, etc.)

Establishment of JV with Accenture for back-office operations

Early Retirement Program

Continue to promote the following initiatives to build a human resource portfolio that enables growth

- Appointment of external human resources (Strategic recruitment)
- Develop human resources who can respond to globalization
- Transform into an organizational culture prepared to address the challenges of the future



3. Shareholder Return



Acquisition of Own Shares and Cancellation of Treasury Shares

- Acquisition of own shares in consideration of the stock price level, which we believe is undervalued, and of our performance trend
- A record high of 75 billion yen (upper limit)

Share buyback


• Total number of shares to be acquired: 12,500,000 shares (maximum)

- Total amount of acquisition cost: 75 billion yen (maximum)
- Period of acquisition: August 1, 2023, to March 31, 2024

Depending on investment opportunities, market environment and other factors, it is possible that no share repurchase, or a share repurchase of only a portion of the above, will be carried out.

Cancellation of treasury shares

- Number of shares to be cancelled : All of the shares acquired
- Scheduled date of cancellation: April 17, 2024 (planned)






Appendix



STS2030 Revision: New Growth to Realize the 2030 Vision

- Continued growth of HIV franchise
- Growth centered around ensitrelvir (STS Phase 2: 2023-25)
- Growth toward realizing the 2030 Vision through aggressive investment (R&D, business investments) (-2030)






Ensitrelvir: Overall Picture of the Current Situation and Future Plans

From the Fiscal 2022 **Financial Results** (Partially revised)

With the emergence of new mutant strains, the need for antiviral drugs remains Accumulating further evidence for the role of Xocova in "with COVID" phase



* NIH sponsored trial *2Post Exposure Prophylaxis Study *3 First Patient In

S-309309: Profile

Indication

Obesity

Product characteristics

- Best-in-class efficacy among existing oral drugs (weight loss of 10% or more per year) with no safety concern
- Lower economic burden compared to GLP-1^{*1} injectables

Market

- Obese patients^{*2}: 245 million (7MM^{*3}), 125 million (U.S.)
- Market size^{*4}: \$ 1,692 MM (2021) (including 93% in the US)




Unmet needs

 There is a demand for a drug that has no safety concerns, shows a sufficient weight loss effect over a long period of time, and has a low out-of-pocket cost

Mechanism of action

Monoacylglyceroltransferase 2 (MGAT2^{*5}) inhibitor



*1 glucagon-like peptide-1

*2 © 2021 DR/Decision Resources, LLC. All rights reserved. Reproduction, distribution, transmission or publication is prohibited. Reprinted with permission.

*3 7 major markets; US, France, Germany, Italy, Spain, UK and Japan

*4 Copyright © 2022 IQVIA. Calculated by SHIONOGI based on IQVIA Analytics Link 2021.1-12, Reprinted with permission *5 monoacylglycerol acyltransferase 2



Resiniferatoxin: Profile

Indication

Osteoarthritis of the knee

⇒ Moderate to severe pain associated with knee osteoarthritis in patients who have failed one or more prior therapies

Special characteristics

• An injection that can reduce pain and improve functionality by injecting into the knee joint once every six months on average


Market

Number of symptomatic people: 25 million (Japan)



Unmet needs

- Insufficient efficacy or short duration of effect is a problem with existing drugs, and there is a need for drugs that can control pain for a long time
- Drugs with strong analgesic effects are required as adjuvants for exercise therapy




- 1. Resiniferatoxin acts on TRPV1* on sensory nerves projecting into the knee surface
- 2. Causes strong desensitization and retraction of sensory nerves from the knee (pain is suppressed)




Pipeline: Infectious Disease

as of July 30, 2023



Pipeline: QOL Diseases with High Social Impact

as of July 30, 2023



Other Major Progress*

• May

- Orphan Drug Designation for Redasemtide for Dystrophic Epidermolysis Bullosa
- Concluded a comprehensive partnership agreement with the Rohto Children's Future Foundation
- Contribution to the Global Health Innovative Technology Fund (GHIT Fund) for the Third Phase

• June

- Selected as a new "DX Featured Company 2023"
- Launch of the Third Phase for the Mother to Mother SHIONOGI Project New Activities to Support Maternal and Child Health in Kenya and Ghana
- Concluded a business alliance agreement with Allm, a medical ICT company, aiming to build a total care for infectious diseases
- Seven manufacturers sign sublicence agreements with the Medicines Patent Pool to produce generic versions of Shionogi's COVID-19 oral antiviral ensitrelvir to increase access in low- and middle-income countries
- Eddingpharm Announces Approval of Mulpleta® (Lusutrombopag) in China

• July

 Shionogi Filed for a Supplemental New Drug Application of XOFLUZA® (Baloxavir Marboxil) in Taiwan for Pediatrics Aged 5 to Under 12 for the Treatment and Prevention of Influenza Infection



Forward-Looking Statements

- Forecast or target figures in this material are neither official forecasts of earnings and dividends nor guarantee of target, achievement and
 forecasts, but present the midterm strategies, goals and visions. Official earnings guidance should be referred to in the disclosure of the annual
 financial report (kessan tanshin) in accordance with the rules set by Tokyo Stock Exchange.
- Materials and information provided during this presentation may contain so-called "forward-looking statements". These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements.
- Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions such as
 interest rate and currency exchange fluctuations. Risks and uncertainties particularly apply with respect to product-related forward-looking
 statements. Product risks and uncertainties include, but are not limited to, technological advances and patents attained by competitors;
 challenges inherent in new product development, including completion of clinical trials; claims and concerns about product safety and efficacy;
 regulatory agency's examination period, obtaining regulatory approvals; domestic and foreign healthcare reforms; trend toward managed care
 and healthcare cost containment; and governmental laws and regulations affecting domestic and foreign operations.
- For products that are approved, there are manufacturing and marketing risks and uncertainties, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials, and failure to gain market acceptance.
- Shionogi disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
- This material is presented to inform stakeholders of the views of Shionogi's management but should not be relied on solely in making investment and other decisions.
- You should rely on your own independent examination of us before investing in any securities issued by our company. Shionogi shall accept no
 responsibility or liability for damage or loss caused by any error, inaccuracy, misunderstanding or changes of target figures or any other use of
 this material.
- This English presentation was translated from the original Japanese version. In the event of any inconsistency between the statements in the two versions, the statements in the Japanese version shall prevail.

